13.87
0.61 (4.60%)
| Penutupan Terdahulu | 13.26 |
| Buka | 13.31 |
| Jumlah Dagangan | 6,452,251 |
| Purata Dagangan (3B) | 4,897,208 |
| Modal Pasaran | 1,649,550,848 |
| Harga / Jualan (P/S) | 21.20 |
| Harga / Buku (P/B) | 2.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -726.57% |
| EPS Cair (TTM) | -5.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -42.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.29% |
| Nisbah Semasa (MRQ) | 4.90 |
| Aliran Tunai Operasi (OCF TTM) | -377.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -150.18 M |
| Pulangan Atas Aset (ROA TTM) | -30.12% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Intellia Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.38 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.98% |
| % Dimiliki oleh Institusi | 97.04% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 31 Dec 2025 | 3,702,995 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 48.00 (Canaccord Genuity, 246.07%) | Beli |
| Median | 28.50 (105.48%) | |
| Rendah | 15.00 (RBC Capital, 8.15%) | Pegang |
| 15.00 (Wells Fargo, 8.15%) | Pegang | |
| Purata | 27.63 (99.21%) | |
| Jumlah | 6 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 13.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jones Trading | 04 Mar 2026 | 29.00 (109.08%) | Beli | 13.82 |
| Canaccord Genuity | 03 Mar 2026 | 48.00 (246.07%) | Beli | 13.61 |
| Citizens | 03 Mar 2026 | 28.00 (101.87%) | Beli | 13.61 |
| HC Wainwright & Co. | 03 Mar 2026 | 30.00 (116.29%) | Beli | 13.61 |
| Leerink Partners | 03 Mar 2026 | 29.00 (109.08%) | Beli | 13.61 |
| RBC Capital | 03 Mar 2026 | 15.00 (8.15%) | Pegang | 13.61 |
| Wells Fargo | 03 Mar 2026 | 15.00 (8.15%) | Pegang | 13.61 |
| Chardan Capital | 02 Mar 2026 | 27.00 (94.66%) | Beli | 15.44 |
| 27 Feb 2026 | 26.00 (87.45%) | Beli | 13.78 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Apr 2026 | CNBC | Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial |
| 06 Feb 2026 | Pengumuman | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |